Recombinant Technologies is focused on developing innovative therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. Their flagship product, AmyTrap-3, is designed to address the unmet medical needs associated with beta-amyloidopathies, which are linked to Alzheimer's and similar conditions. The company aims to alleviate symptoms without causing pain or suffering to patients, emphasizing the importance of improving the quality of life for those affected. Their approach involves the use of beta-amyloid capturing molecules that have been proof-of-concept tested and pre-clinically validated, indicating a strong foundation for clinical application.

The company has also introduced the AmyTrapper™, a plasma-filtration column that serves as a vehicle for the clinical application of the AmyTrap molecule. This technology is part of their broader mission to develop small molecules that can effectively reduce beta-amyloid levels in circulation, thereby potentially mitigating the effects of Alzheimer's disease. With over $2 million invested in the development of these technologies, Recombinant Technologies is committed to making a significant clinical impact on neurodegenerative diseases through their patented and innovative therapeutic solutions.

United States

Recombinant Technologies, LLC, is an emerging biotechnology company focused on developing therapeutics for neurodegenerative diseases. This innovative Bio-Technology company will ... Plasma lipids and lipoprotein profile in coronary heart disease and in healthy volunteers in South ... Recombinant Technologies and life sciences research enabler and commercialization expert.

Recombinant Technologies

Company Details